Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: YPEL3

Gene summary for YPEL3

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

YPEL3

Gene ID

83719

Gene nameyippee like 3
Gene AliasYPEL3
Cytomap16p11.2
Gene Typeprotein-coding
GO ID

GO:0006950

UniProtAcc

A0A024R624


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
83719YPEL3P20T-EHumanEsophagusESCC4.95e-123.32e-010.1124
83719YPEL3P21T-EHumanEsophagusESCC1.81e-192.45e-010.1617
83719YPEL3P22T-EHumanEsophagusESCC6.88e-263.53e-010.1236
83719YPEL3P23T-EHumanEsophagusESCC1.29e-257.24e-010.108
83719YPEL3P24T-EHumanEsophagusESCC2.59e-142.29e-010.1287
83719YPEL3P26T-EHumanEsophagusESCC9.63e-143.68e-010.1276
83719YPEL3P27T-EHumanEsophagusESCC1.52e-162.22e-010.1055
83719YPEL3P28T-EHumanEsophagusESCC1.08e-296.89e-010.1149
83719YPEL3P30T-EHumanEsophagusESCC5.35e-145.57e-010.137
83719YPEL3P31T-EHumanEsophagusESCC1.49e-143.06e-010.1251
83719YPEL3P32T-EHumanEsophagusESCC9.76e-061.21e-010.1666
83719YPEL3P36T-EHumanEsophagusESCC3.78e-071.41e-010.1187
83719YPEL3P37T-EHumanEsophagusESCC1.74e-102.39e-010.1371
83719YPEL3P38T-EHumanEsophagusESCC1.30e-092.20e-010.127
83719YPEL3P39T-EHumanEsophagusESCC2.41e-307.94e-010.0894
83719YPEL3P40T-EHumanEsophagusESCC3.69e-175.51e-010.109
83719YPEL3P42T-EHumanEsophagusESCC6.77e-091.76e-010.1175
83719YPEL3P44T-EHumanEsophagusESCC4.11e-151.76e-010.1096
83719YPEL3P47T-EHumanEsophagusESCC1.15e-052.15e-010.1067
83719YPEL3P48T-EHumanEsophagusESCC4.70e-132.48e-010.0959
Page: 1 2 3 4 5 6 7 8 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
BreastThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.IDC: Invasive ductal carcinoma
DCIS: Ductal carcinoma in situ
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:00075688BreastPrecanceraging41/1080339/187235.95e-061.71e-0441
GO:00075694BreastPrecancercell aging17/1080132/187231.55e-031.59e-0217
GO:00903423BreastPrecancerregulation of cell aging10/108061/187232.40e-032.21e-0210
GO:000756813BreastIDCaging52/1434339/187231.14e-065.10e-0552
GO:000756912BreastIDCcell aging19/1434132/187235.63e-034.08e-0219
GO:00903421BreastIDCregulation of cell aging11/143461/187236.10e-034.36e-0211
GO:000756823BreastDCISaging50/1390339/187232.38e-068.46e-0550
GO:000756921BreastDCIScell aging19/1390132/187234.03e-033.20e-0219
GO:00903422BreastDCISregulation of cell aging11/139061/187234.84e-033.67e-0211
GO:0007568ColorectumADaging98/3918339/187232.77e-043.39e-0398
GO:00075681ColorectumMSSaging90/3467339/187231.51e-042.19e-0390
GO:000756820EsophagusESCCaging201/8552339/187232.64e-073.94e-06201
GO:00075699EsophagusESCCcell aging81/8552132/187232.00e-041.27e-0381
GO:00903984EsophagusESCCcellular senescence54/855293/187231.08e-023.67e-0254
GO:000756812LiverCirrhoticaging117/4634339/187233.13e-053.91e-04117
GO:000756822LiverHCCaging185/7958339/187234.28e-065.50e-05185
GO:00075691LiverHCCcell aging73/7958132/187232.00e-031.01e-0273
GO:000756818Oral cavityOSCCaging194/7305339/187236.18e-122.33e-10194
GO:00075698Oral cavityOSCCcell aging73/7305132/187231.05e-047.75e-0473
GO:00903983Oral cavityOSCCcellular senescence48/730593/187239.03e-033.26e-0248
Page: 1 2 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
YPEL3SNVMissense_Mutationnovelc.345C>Gp.Ile115Metp.I115MP61236protein_codingdeleterious(0)probably_damaging(0.921)TCGA-ZJ-AAXB-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
YPEL3deletionFrame_Shift_Delc.104delNp.Pro35ArgfsTer59p.P35Rfs*59P61236protein_codingTCGA-AD-6889-01Colorectumcolon adenocarcinomaMale>=65I/IIChemotherapyxelodaPD
YPEL3SNVMissense_Mutationnovelc.413N>Gp.Tyr138Cysp.Y138CP61236protein_codingdeleterious(0)probably_damaging(1)TCGA-A5-A0G2-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnknownUnknownSD
YPEL3SNVMissense_Mutationrs755667144c.194N>Ap.Arg65Hisp.R65HP61236protein_codingtolerated(0.1)benign(0.168)TCGA-A5-A0G2-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVUnknownUnknownSD
YPEL3SNVMissense_Mutationnovelc.94C>Ap.Pro32Thrp.P32TP61236protein_codingtolerated_low_confidence(0.12)benign(0.027)TCGA-A5-A2K5-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
YPEL3SNVMissense_Mutationnovelc.52N>Ap.Leu18Metp.L18MP61236protein_codingdeleterious_low_confidence(0.02)probably_damaging(0.934)TCGA-AP-A059-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
YPEL3SNVMissense_Mutationnovelc.239A>Gp.Gln80Argp.Q80RP61236protein_codingtolerated(0.21)probably_damaging(0.948)TCGA-50-5066-01Lunglung adenocarcinomaMale>=65I/IIChemotherapycarboplatinSD
YPEL3SNVMissense_Mutationnovelc.158N>Tp.Asp53Valp.D53VP61236protein_codingdeleterious(0.05)benign(0.138)TCGA-85-8355-01Lunglung squamous cell carcinomaMale<65I/IIUnknownUnknownSD
YPEL3SNVMissense_Mutationnovelc.275N>Cp.Val92Alap.V92AP61236protein_codingtolerated(0.23)benign(0.254)TCGA-CV-A45Z-01Oral cavityhead & neck squamous cell carcinomaMale>=65I/IIUnknownUnknownPD
YPEL3SNVMissense_Mutationnovelc.34N>Tp.Leu12Phep.L12FP61236protein_codingtolerated_low_confidence(0.06)benign(0.144)TCGA-F7-A50I-01Oral cavityhead & neck squamous cell carcinomaMale>=65I/IIUnknownUnknownSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1